Incidence and Risk of Glucocorticoid‐Associated Adverse Effects in Patients With Rheumatoid Arthritis

• Published in: Arthritis care & research (2010) Vol. 71; no. 4; pp. 498 - 511
• Main Authors: Wilson, Jessica C., Sarsour, Khaled, Gale, Sara, Pethö‐Schramm, Attila, Jick, Susan S., Meier, Christoph R.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.04.2019
• Subjects: Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - mortality; Bleeding; Cardiovascular Diseases - chemically induced; Cardiovascular Diseases - epidemiology; Case-Control Studies; Cerebral infarction; Diabetes mellitus; Diabetes Mellitus - chemically induced; Diabetes Mellitus - epidemiology; Female; Gastrointestinal Hemorrhage - chemically induced; Gastrointestinal Hemorrhage - epidemiology; Glaucoma; Glaucoma - chemically induced; Glaucoma - epidemiology; Glucocorticoids; Glucocorticoids - adverse effects; Health risk assessment; Humans; Hypertension; Incidence; Intestinal Perforation - chemically induced; Intestinal Perforation - epidemiology; Male; Middle Aged; Myocardial infarction; Osteoporosis; Osteoporosis - chemically induced; Osteoporosis - epidemiology; Rheumatoid arthritis; United Kingdom - epidemiology; United Kingdom
• ISSN: 2151-464X; 2151-4658
• DOI: 10.1002/acr.23611

Objective Using the UK Clinical Practice Research Datalink, we examined the incidence of glucocorticoid (GC)‐related serious adverse events (SAEs) in rheumatoid arthritis (RA) and non‐RA patients and quantified the risk of SAEs in patients with RA. Methods We matched incident patients with RA to an age‐ and sex‐matched, non‐RA comparison group of equal size. In a cohort analysis, we estimated incidence rates (IRs) and IR ratios (IRRs) for GC‐related AEs (i.e., diabetes mellitus [DM], osteoporosis, fractures, glaucoma, hypertension, gastrointestinal [GI] perforation or bleeding, thrombotic stroke or myocardial infarction [MI], or death), stratified by GC use. We conducted a series of nested case–control analyses among patients with RA, evaluating the effects of increasing cumulative and average daily GC dose. Cases of each outcome were matched to controls for age, sex, and general practice. We calculated adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) for each outcome. Results Patients with RA had a higher incidence for all investigated SAEs except glaucoma, compared to non‐RA patients. IRRs were greater in those patients prescribed a GC than in those without. In patients with RA, GCs were associated with an elevated risk of DM (adjusted OR 1.33 [95% CI 1.14–1.56]), osteoporosis (adjusted OR 1.41 [95% CI 1.25–1.59]), thrombotic stroke or MI (adjusted OR 1.28 [95% CI 1.07–1.52]), serious infection (adjusted OR 1.28 [95% CI 1.11–1.48]), and death (adjusted OR 1.33 [95% CI 1.19–1.48]). There was a trend of increasing risk with increasing cumulative and average daily GC dose for all outcomes other than glaucoma, hypertension, and GI perforations or bleeding (P < 0.05). Conclusion Patients with RA had an increased incidence of GC‐related AEs. Increasing cumulative and average daily GC doses were found to be associated with an increasing risk of developing an AE.